- 1 Comparative gene regulatory networks modulating APOE expression in microglia
- 2 and astrocytes

3

- 4 Logan Brase<sup>1,2</sup>, Yanbo Yu<sup>1,2</sup>, Eric McDade<sup>3</sup>, Dominantly Inherited Alzheimer Network (DIAN)°,
- 5 Oscar Harari<sup>1,2,4,¶</sup>, Bruno A. Benitez<sup>5,¶,\*</sup>

6

- 7 Affiliations:
- 8 1. Department of Psychiatry, Washington University, Saint Louis, St. Louis, Missouri, United States of America
- 9 2. The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University, St. Louis,
- 10 Missouri, United States of America
- 11 3. Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
- 4. Department of Neurology, Division of Neurogenetics, The Ohio State University, Columbus, OH, United States
- 13 of America
- 14 5. Department of Neurology and Neuroscience, Harvard Medical School and Beth Israel Deaconess Medical
- 15 Center, Boston, Massachusetts, United States of America

- ° A list of authors and their affiliations appears at the end of the paper.
- 18 ¶ Equally contributing senior author
- 19 \* Corresponding author
- 20 E-mail: bbenitez@bidmac.harvard.edu

### Abstract

**Background**: Single-cell technologies have unveiled various transcriptional states in different brain cell types. Transcription factors (TFs) regulate the expression of related gene sets, thereby controlling these diverse expression states. Apolipoprotein E (*APOE*), a pivotal risk-modifying gene in Alzheimer's disease (AD), is expressed in specific glial transcriptional states associated with AD. However, it is still unknown whether the upstream regulatory programs that modulate its expression are shared across brain cell types or specific to microglia and astrocytes.

**Methods**: We used pySCENIC to construct state-specific gene regulatory networks (GRNs) for resting and activated cell states within microglia and astrocytes based on single-nucleus RNA sequencing data from AD patients' cortices from the Knight ADRC-DIAN cohort. We then identified replicating TF using data from the ROSMAP cohort. We identified sets of genes coregulated with *APOE* by clustering the GRN target genes and identifying genes differentially expressed after the virtual knockout of TFs regulating *APOE*. We performed enrichment analyses on these gene sets and evaluated their overlap with genes found in AD GWAS loci.

**Results**: We identified an average of 96 replicating regulators for each microglial and astrocyte cell state. Our analysis identified the CEBP, JUN, FOS, and FOXO TF families as key regulators of microglial APOE expression. The steroid/thyroid hormone receptor families, including the THR TF family, consistently regulated APOE across astrocyte states, while CEBP and JUN TF families were also involved in resting astrocytes. AD GWAS-associated genes (*PGRN*, *FCGR3A*, *CTSH*, *ABCA1*, *MARCKS*, *CTSB*, *SQSTM1*, *TSC22D4*, *FCER1G*, and HLA genes) are co-regulated with APOE. We also uncovered that APOE-regulating TFs were linked to circadian rhythm (*BHLHE40*, *DBP*, *XBP1*, *CREM*, *SREBF1*, *FOXO3*, and *NR2F1*).

**Conclusions**: Our findings reveal a novel perspective on the transcriptional regulation of *APOE* in the human brain. We found a comprehensive and cell-type-specific regulatory landscape for *APOE*, revealing distinct and shared regulatory mechanisms across microglia and astrocytes, underscoring the complexity of *APOE* regulation. *APOE*-co-regulated genes might also affect AD risk. Furthermore, our study uncovers a potential link between circadian rhythm disruption and *APOE* regulation, shedding new light on the pathogenesis of AD.

Keywords: Alzheimer Disease, APOE, single-nucleus RNA-seq, gene regulatory networks, microglia, astrocyte

# Introduction

56

57 Alzheimer disease (AD) is a progressive neurodegenerative disorder that affects millions of 58 people worldwide. It is characterized by cognitive impairment, memory loss, and behavioral 59 changes. The strongest genetic risk modifiers are variants in the gene APOE. It is involved in lipid 60 transport and metabolism in the brain and has two primary variants that influence disease risk, 61 e2 (protective) and e4 (risk). APOE is constitutively expressed in astrocytes and activated 62 microglia<sup>1</sup>, cell types that are key players in neuroinflammation and neurodegenerative 63 processes<sup>2</sup>. 64 When activated, microglial cells can significantly upregulate APOE expression, a process that is 65 crucial for the phagocytic clearance of amyloid-beta and other debris<sup>3</sup>. Astrocytes, utilize APOE 66 to support the lipid and energy demands of the surrounding neurons<sup>4</sup>. The  $\varepsilon$ 4 allele, in 67 particular, has been associated with a detrimental effect on microglial activation and astrocytic 68 function, exacerbating neuroinflammatory and neurodegenerative processes<sup>2–4</sup>. These 69 expression states are not static; they evolve in response to the brain's pathological environment, 70 influencing disease progression and severity. Understanding the differences in APOE expression 71 regulation between microglial and astrocytic cell states can provide valuable insights into the 72 molecular mechanisms underlying APOE's involvement in AD and potentially other 73 neurodegenerative disorders. 74 In this study, we aimed to further investigate the differences in the regulation of APOE 75 expression between various microglial and astrocytic cell states using single-nucleus RNA-seq 76 (snRNA-seq). To this end, we performed state-specific gene regulatory network (GRN) analysis 77 using pySCENIC on specific cell states (Figure 1). We then used two approaches to identify gene 78 sets co-regulated with APOE in these networks: co-regulatory network clusters and transcription 79 factor knockout (TF-KO) differentially expressed genes (DEGs). We assessed the relevance of 80 these gene sets to AD by testing their overlap with AD genome-wide association study (GWAS) 81 genes and their enrichment in AD-related pathways. By delineating the GRNs in these critical 82 cell states, we seek to elucidate the distinct transcriptional regulatory mechanisms that govern 83 APOE expression, which is crucial for unraveling the complex interplay between APOE regulation 84 and AD pathogenesis. This knowledge may lead to the development of targeted therapeutic

# 86 progression.




Figure 1 Analysis workflow
We extracted microglial and astrocytic cell states and ran them individually through pySCENIC to create state-specific GRNs. We replicated the putative pySCENIC-TFs by integrating microglia and astrocytes from the ROSMAP cohort and running pySCENIC on them. We clustered the target genes into co-regulatory networks and virtually knocked out the transcription factors (TF KO) that regulated APOE. We identified genes co-regulated with APOE using co-regulatory network clusters and TF-KO DEGs. Both sources

of gene sets were tested for inclusion of AD GWAS genes and gene set enrichment.

### Results

### Cell-state-specific transcription factors modulating APOE expression

To identify the state-specific TF regulators of *APOE*, we utilized snRNA-seq data from the Knight ADRC and DIAN cohorts (parietal, n=67)<sup>5</sup>, and replicated the TFs in snRNA-seq from the ROSMAP cohort (dorsolateral prefrontal cortex, n=32)<sup>6</sup>. Focusing on microglia and astrocytes, the principal *APOE* expressors<sup>1</sup>, we isolated the resting and activated states for each cell type: mic-resting (n=7,032), mic-activated (n=3,662), mic-inflammatory (n=1,669), astro-resting (n=21,010), and astro-activated (n=10,028). We leveraged pySCENIC<sup>7</sup> to build a GRN for each state, and detected an average of 117 and 109 reproducible TF regulators for Knight and ROSMAP cohorts respectively (Supplementary Table 1). We compared the putative TFs between the cohorts and identified an average of 96 replicating regulators for each cell state (Figure 2, Supplementary Table 1). Among these, 35 TFs were shared by all five states, including *ARID3A* (*ABCA7* locus), *GABPA* (*APP* locus), and *MAF* (*WWOX* locus), which are within AD GWAS loci<sup>8</sup> (Supplementary Table 2). Moreover, 59 TFs were shared by the microglia states, including *SPI1*, *IKZF1*, *TCF3* (*KLF16* locus), and *GABPB1* (*SPPL2A* locus), which are within AD GWAS loci<sup>8,9</sup>, and 69 TFs were shared by the astrocyte states including *SREBF1* (*MYO15A* locus) and *ZNF518A* (*BLNK* locus).




Figure 2 Inclusive intersection of state-specific TF regulators

TF sets were identified by individually running pySCENIC on the Knight/DIAN and ROSMAP cell states and isolating the intersecting TFs between the discovery and replication runs (see Methods). The TF sets were then compared in an upset plot. The inclusive intersection indicates that all subsets are counted in the superset. For example, all 35 TFs shared between all cell states (the lowest subset) are counted in all other sets. The red column indicates the TFs that are common between all microglia states. The blue column indicates that TFs that are common between both astrocyte cell states.

119 Different TF families regulate APOE between microglia and astrocytes 120 Next, we pinpointed the TFs regulating APOE in each state. In the mic-resting GRN, APOE was 121 regulated by CEBPA, CEBPB, CEBPD, IRF7, and JUND TFs. In the mic-activated and mic-122 inflammatory GRNs, APOE was regulated by CEBPB, CEBPD, and JUNB, with IRF7 also involved in 123 the mic-activated state. In the astrocytic GRNs, APOE was regulated by JUN and THRA in the 124 resting state and by THRB in the activated state. 125 These results highlight the CCAAT/enhancer-binding protein (CEBP) family of TFs, which form 126 homo- and heterodimers to precisely control the expression of target genes that are primarily 127 immune-related<sup>10</sup>. In mouse microglia cell cultures, CEBPA was shown to regulate homeostatic and anti-inflammatory DAM genes<sup>11</sup>, and in mouse models, CEBPB modulates APOE 128 expression<sup>12</sup>. These findings validate pySCENIC's ability to capture known biology and lends 129 130 credence to the other findings. In addition, CEBPD was shown to boost the expression of activation genes, including NOS2, C6, IL1B, and IL6 in a BV2 microglia cell line<sup>13</sup>. Intriguingly, LPS 131 treatment upregulates CEBPB and CEBPD while downregulating CEBPA, implying contrasting 132 133 regulatory functions. This could account for CEBPA's role as an APOE regulator only in mic-134 resting, but not in mic-activated and mic-inflammatory. 135 IRF plays a crucial role in the immune response. IRF7 regulates type I interferon genes and  $IL6^{14}$ . 136 The JUN family proteins are known to be involved in various cellular processes, including proliferation, apoptosis, and immune response 15. Their role in regulating APOE expression 137 138 suggests a potential link between APOE and these cellular processes. 139 Thyroid hormone receptor family proteins, including THRA and THRB, bind to thyroid hormone, 140 which plays a crucial role in metabolism, growth, and development. Using cell lines, THRB was 141 shown to upregulate APOE expression in astrocytes by forming a complex with RXRA and binding to the multienhancer ME.2 which activates the APOE promoter<sup>16</sup>. Once again, this 142 143 shows that pySCENIC identifies true regulatory relationships. 144 Our findings suggest that CEBPB and THRB regulate APOE expression in the human brain, in 145 concordance with studies in model systems. The GRNs from pySCENIC suggest that the CEBP 146 family primarily regulates APOE in microglia, while the THR family chiefly regulates expression in 147 astrocytes. This is in line with CEPB regulating immunity genes and microglia being the primary

immune cells in the brain, as well as THR influencing metabolism and astrocytes being the primary support cells for neurons. This does not exclude the possibility that both families may influence *APOE* expression in both cell types.

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

148

149

150

APOE-associated target genes were regulated by TFs linked to the circadian rhythm We aimed to explore those genes co-regulated with APOE. Thus, we built a complex coregulatory network of genes, including all the putative TFs predicted by pySCENIC and their respective regulated genes. Then, we clustered the target genes into a UMAP space using the 86-101 TFs signatures that defined each cell state. We identified an average of 27 gene clusters in each expression state (Figure 3, Supplementary Table 1). The gene clusters containing APOE comprised an average of 327 genes regulated by an average of 13 TFs for each cell state (Supplementary Table 1). To validate these gene clusters, we isolated the TFs that significantly upregulated the gene clusters containing APOE, a known activated marker gene, and CX3CR1 and P2RY12, known homeostatic marker genes, in the three microglia clusters. We then performed a virtual knockout (KO) of these TFs and observed the shift in the expression profile of the cells. We adapted the virtual TF knockout method described in SCENIC+17 to work with pySCENIC outputs. Following the knockout of the TF, this method propagates the change through the rest of the gene expression matrix (GEM) producing a perturbed expression profile and an associated visualization of the shift in the reduced dimensionality space. The TFs regulating these homeostatic and activated marker genes should have opposite influences on microglial activation, thus opposing shifts in the expression profiles. In the mic-resting state, an individual knockout of the TFs associated with the APOE gene cluster generally shifted cells toward the mic-resting state, indicating these TFs are involved in maintaining an activated state. Conversely, individual knockouts of seven of the 14 TFs associated with the CX3CR1 and P2RY12 clusters generally pointed away from the mic-resting state, suggesting these TFs promote a resting state (Supplementary Figure 1). A similar trend was seen within mic-activated, with KO of all 17 APOE TFs pointing away from mic-activated and eight of the 19 TFs<sup>CX3CR1/P2RY12+</sup> pointing toward micactivated (Supplementary Figure 2). This indicates that the clustering groups mirror the

178 CX3CR1 or P2RY12 clusters, so it was not explored for validation. 179 We then explored the TFs regulating APOE in each state. The mic-resting APOE cluster was 180 regulated by BHLHE40, CEBPG, FOS, FOSL2, GABPA, ILF2, JUN, JUNB, KMT2B, REL, and XBP1, in 181 addition to the TFs directly regulating APOE mentioned previously (Figure 3A, Supplementary 182 Figure 4A). BHLHE40 regulates the circadian rhythm, negatively regulates itself, DBP (another 183 circadian gene), and represses RXR, a component of APOE activation through the THR family of 184 TFs<sup>18–21</sup>. BHLHE40 is located within an AD African-American GWAS locus is a key regulator for clearing lipid-rich cellular debris by lipid-associated macrophages (LAMs)<sup>8,22</sup>. XBP1 becomes a 185 functional TF in response to endoplasmic reticulum stress induced by unfolded proteins and is 186 modulated by the circadian rhythm<sup>23,24</sup>. The mic-activated APOE cluster included BHLHE40, 187 188 CEBPA, CEBPG, CHD1, CREM, ETS2, FOS, FOSL2, FOXO1, FOXO3, JUND, SP3, SREBF1, and USF2, but not IRF7, compared to APOE alone (Figure 3B, Supplementary Figure 4B). CREM and SREBF1 189 190 are related to circadian rhythm and SREBF1 is additionally related to lipid metabolism<sup>25,26</sup>. 191 Upregulation of FOXO3 and two other TFs, was shown to move weakly inflammatory microglia to a strongly inflammatory state in a cell line<sup>27</sup>. Additionally, FOXO3 is deactivated by SIRT1, 192 193 another gene associated with circadian rhythm<sup>28</sup>. The mic-inflammatory APOE gene cluster added CEBPA, E2F4, FOSL2, GABPB1, HDX, ILF2, IRF7, JUN, JUND, KMT2B, MAF, MAFG, NFE2L1, 194 195 NR3C1, TCF7L2, and ZBTB40 to the APOE TF list (Figure 3C, Supplementary Figure 4C). E2F4 halts 196 the cell cycle and has been linked to cell quiescence, regulation of AD-related gene networks, and upregulation in AD brains<sup>29</sup>. Macrophage/microglia activation factor (MAF) expression has 197 been linked to changes in the endosome/lysosome membranes<sup>30</sup>, which suggests a concerted 198 199 action between APOE and endo-/lysosomal function in activated microglia. Taken together, the 200 CEBP, FOS, and JUN families regulate the APOE gene clusters across microglial cell states. 201 The APOE clusters within astrocytes were regulated by fewer TFs than their microglial 202 counterparts. Interestingly, astro-resting did not include either of the THR-related TFs. However 203 it included another steroid/thyroid hormone family receptor NR2F131 (Figure 3D, 204 Supplementary Figure 4D), which is associated with Bosh-Boonstra-Schaaf optic atrophy 205 (BBSOA), optic nerve atrophy featured by the loss of retinal ganglion cells critical for the light

expected biology. The mic-inflammatory cluster had no TFs significantly upregulating the

entrainment of the circadian rhythm<sup>32,33</sup>. The APOE cluster in astro-resting also had TFs DBP, CEBPB, ING4, JUND, and TBP (Figure 3D, Supplementary Figure 4D). This supports the idea that the CEBP family of TFs influences APOE in astrocytes and microglia. As previously noted, DBP is related to the circadian rhythm. Astro-activated had MAFG, NFIC, NR2F1, PBX1, POU3F2, RARB, RFX3, and TCF7L1 regulating the APOE gene cluster in addition to THRB which directly regulated APOE in this cell state (Figure 3E, Supplementary Figure 4E). MAFG has been implicated in astrocyte-driven inflammation linked to the chronic inflammatory disease, multiple sclerosis<sup>34</sup>. TCF7L1 is important for astrocyte maturation, highlighting the central role that APOE plays in normal astrocyte function<sup>35</sup>. RARB is another steroid/thyroid hormone family receptor that forms heterodimers with RXR to facilitate transcriptional activation or repression. Despite the absence of the THR-related TFs in astro-resting, both APOE gene clusters were regulated by steroid/thyroid hormone receptors, suggesting expression regulation through thyroid hormone. Overall, we observed that circadian rhythm-related TFs were associated with regulating the APOE gene clusters across cell types and states. This implies that APOE participates in processes similar to those regulated by these TFs, even if they do not directly regulate APOE. Alternatively, these TFs may have a role in APOE regulation, but the pySCENIC analysis may lack the power to detect them.

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223224

225

226

227

228




Figure 3 UMAP representation of gene regulatory networks

A-E) A global UMAP visualization of each cell states' regulome along with a zoomed view highlighting APOE. Principle
component analysis was performed on the TF-by-target gene matrix. The top five principal components were used to calculate
the UMAP coordinates. APOE is underlined. The TFs in red directly regulate APOE. TFs in black significantly upregulate the APOE
gene cluster. TFs in blue are the TFs that were replicated in the ROSMAP dataset. D) The global UMAP for Astro-resting is
zoomed. The full figure can be found in Supplementary Figure 3.

#### Gene set enrichment of APOE gene clusters

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

To investigate the pathways behind the genes within the APOE gene clusters from the coregulatory networks, we performed an enrichment analysis using Gene Ontology (GO) biological process (BP) terms. Mic-resting showed an enrichment of pathways related to cytoplasmic translation, cytokine production, apoptotic process, integrated stress response, immunoglobulin-mediated immune response, response to lipid, IL-6 production, and response to LPS (Supplementary Figure 4F, Supplementary Table 3a). Mic-activated shared most of these pathways, but also the glycolytic process (Supplementary Figure 4F, Supplementary Table 3b), which is a metabolic feature of AD<sup>36</sup>. Mic-inflammatory had fewer pathways than the other two microglial states, but they included endocytosis, macroautophagy, and cotranslational protein targeting to the membrane (Supplementary Figure 4F, Supplementary Table 3c). These results imply that the genes in this cluster are related to the uptake and degradation of extracellular material and the replenishment of membrane proteins. Astro-resting was enriched for genes in mitochondrial electron transport, NADH to ubiquinone and other aspects of the electron transport chain. It also had genes related to Golgi vesicle transport and synapse organization (Supplementary Figure 4F, Supplementary Table 3d). These results reflect the roles of astrocytes in energy metabolism and synaptic modulation. Astroactivated had many genes in its APOE cluster (n=409), which made the enrichment analysis less sensitive. None of the GO terms passed multiple testing correction, but the top hits (p-value < 0.01) included terms such as semaphorin-plexin signaling, axon guidance, synapse assembly, fatty-acyl-CoA biosynthetic process, glucan catabolic process, and amide metabolic process (Supplementary Table 3e). Semaphorin-plexin signaling, in conjunction with axon guidance and synapse assembly, suggests an active regulation of the surrounding synapses. Glucan catabolism indicates the cell is low on glucose and tapping into glycogen reserves. Fatty-acyl-CoA biosynthesis and amide metabolism both indicate that resources are being diverted from ATP production through cellular respiration toward the synthesis of lipids like phospholipids and cholesterol for membranes and neurotransmitters, which is consistent with previous findings in  $AD^{37}$ .

Overall, all microglia states were associated with immune, inflammation, and cytokine-related terms. We observed that mic-activated and astro-activated cells had genes related to known metabolic alterations in AD. We also noticed that mic-inflammatory and astro-activated cells had genes involved in endocytosis and autophagy, which are mechanisms for clearing amyloid-beta plaques and recycling other macromolecules.

263264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

258

259

260

261

262

### **Gene set enrichment of TF target genes**

To complement the analysis of the APOE gene clusters, we took a deeper dive into the TFs directly regulating APOE. Specifically, we identified the target genes significantly perturbed by a virtual knockout of these TFs. As previously described, we implemented a modified version of the TF-KO method included in SCENIC+, producing a perturbed expression profile after TF-KO. We then performed a Mann-Whitney rank-sum analysis to identify differentially expressed genes between the original and TF-KO GEMs. We found 60 to 434 nominal DEGs for each TF knockout (Supplementary Table 1, Supplementary Table 4). Using the nominal DEGs, we performed a gene set enrichment analysis and visualized the results in a heatmap to better identify patterns in the regulation of biological processes. CEBPB-regulated processes were common across the microglial states, including positive regulation of cytokine production, receptor-mediated endocytosis, and humoral immune response mediated by circulating immunoglobulin (Figure 4, Supplementary Table 5). These processes reflect the role of CEBPB in modulating the inflammatory response of microglia. However, CEBPB also regulated processes that were specific to certain microglial states. For example, in mic-inflammatory, CEBPB-regulated genes are involved in mRNA splicing, via spliceosome and cellular response to lipopolysaccharide (Figure 4, Supplementary Table 5). In contrast, in mic-activated, CEBPB lacked the terms related to positive regulation of protein phosphorylation, positive regulation of transferase activity, antigen processing and presentation of exogenous peptide antigen, and cellular response to cytokine stimulus (Figure 4, Supplementary Table 5). CEBPD regulated shared processes in mic-resting and -activated, but had a distinct signature in mic-inflammatory. The main divergence between the primary CEBPB and CEBPD signatures was that CEBPD additionally regulated fat differentiation, lipoprotein biosynthesis process, and




Figure 4 Gene set enrichment analysis of the target genes for each cell-state-specific TF regulating APOE
Target genes for each TF were assessed for GO Biological Process terms. Terms were condensed using Revigo. Rows and columns
were sorted using hierarchical clustering on Euclidean distance. Tiles with (.) indicate significance after multiple testing
correction.

JUNB regulated processes related to the immune response in mic-resting and mic-activated states, including negative regulation of the apoptotic process, negative regulation of inflammatory response, cellular response to cytokine stimulus, and humoral immune response mediated by circulating immunoglobulin (Figure 4, Supplementary Table 5). Within mic-activated, it regulated inflammatory response, cellular response to lipopolysaccharide, but also synapse pruning and regulation of mRNA splicing, via splicesome indicating that JUNB regulates

additional processes other than immune roles in microglia. JUND was the regulator in micresting state that also regulated negative regulation of apoptotic process and humoral immune response mediated by circulating immunoglobulin, but uniquely among the JUN family, it also regulated negative regulation of amyloid-beta formation through RIN1 and RIN3, which negatively regulate BACE1. This implies that JUND may be beneficial in preventing amyloid-beta accumulation in AD. Within astro-resting, JUN was the regulator and it had the most divergent profile, regulating processes involved in negative regulation of growth, regulation of cell cycle, regulation of cell population proliferation, cellular response to metal ion, and carbohydrate catabolic process (Figure 4, Supplementary Table 5). THRA target genes were not enriched for any particular GO term, but THRB-regulated genes associated with transcription, negative regulation of inclusion body assembly, positive regulation of neurogenesis, cellular response to oxidative stress, axonogenesis, and regulation of cytokinesis (Figure 4, Supplementary Table 5). These processes suggest that THRB regulates genes that prepare astrocytes for activation and inflammatory response. Overall, this alternative method of examining the genes co-regulated with APOE revealed similar immune, lipid, and energy metabolism pathways to those of the APOE gene clusters, strengthening the validity of these biological pathways with APOE.

# Additional AD GWAS genes are co-regulated with APOE

The identified TFs that regulate *APOE* also regulate other genes in AD GWAS loci. Using the same set of nominal DEGs identified after the TF KO, we isolated the DEGs that intersected the list of genes within AD GWAS loci. Several of the genes are regulated by multiple *APOE* TFs including *PGRN*, *FCGR3A*, *CTSH*, *ABCA1*, *MARCKS*, *CTSB*, *SQSTM1*, *TSC22D4*, *FCER1G*, and several of the HLA genes (Figure 5A,B, Supplementary Figure 5). *PGRN*, *CTSH*, and *CTSB* are all related to lysosome function and are co-regulated with *APOE* in the microglia states. *CTSB* is specifically associated with the proteolytic processing of *APP*<sup>38</sup>. *FCER1G* and *FCGR3A* are in the *ADAMTS4* locus and encode Fc immunoglobulin receptors that bind to IgE and IgG respectively. *CEBPB* regulates *FCER1G* in mic-resting and mic-inflammatory. It represses AD risk genes through the Herpes simplex (HSV-1) escape strategy<sup>39</sup>. *FCGR3A* 

exacerbates neurodegeneration and is a potential link behind the increased AD risk in chronic periodontitis patients<sup>40,41</sup>. It is regulated in mic-resting by CEBPB and IRF7; mic-activated by CEBPB and CEBPD; and mic-inflammatory by CEBPB, and JUNB. ABCA1 is a transporter that transfers cholesterol and other lipids to APOE and there is a link between ABCA1, APOE, and AB levels<sup>42</sup>. APOE and ABCA1 are co-regulated in both astrocyte and microglial states. MARCKS is associated with lipid rafts, dissociates from the membrane at decreased concentrations of cholesterol, causing PIP2 release, and also influences inflammation<sup>43–45</sup>. SQSTM1 (p62), found in the RASGEF1C locus, is also found in both astrocytes and microglia and functions as a bridge between ubiquitinated proteins and autophagosomes<sup>46</sup>. TSC22D4 is within the NYAP1 locus and is regulated in astro-resting by both APOE TFs (THRA and JUN). TSC22D4 participates in forming a complex that degrades BRI2 and BRI3, inhibitors of A $\beta$  production and aggregation. Looking at the APOE gene clusters, we identified genes within the ABCA7 and SCIMP loci across all five cell states and four out of the five states had HLA-DRB1, LILRB2, SIGLEC11, KLF16, DOC2A, and NYAP1 (Figure 5D, Supplementary Figure 5, Supplementary Figure 6). Using SCIMP as an example, mic-resting had gene PFN1 within the APOE gene cluster; mic-activated had CXCL16 and PFN1; mic-inflammatory had CXCL16; astro-resting had SLC25A11; and astroactivated had RABEP1 (Figure 5C). Interestingly, PFN1 is related to amyotrophic lateral sclerosis (ALS), action polymerization, and binding of PIP2<sup>47,48</sup>, which could connect it to MARCKS and, therefore membrane cholesterol concentrations as mentioned above. CXCL16 induces a chemokine-induced chemotactic response, SLC25A11 maintains the organization and morphology of the mitochondrial cristae<sup>49</sup>, and RABEP1 is involved in endocytic membrane fusion and recycling of endosomes, all of which connect to AD biology. Genes in AD loci CD33 and APH1B were exclusively found in both astrocyte states (Figure 5D). LACTB (APH1B locus) was co-regulated with APOE in astro-resting (Figure 5C) and regulated mitochondrial lipid metabolism<sup>50</sup>. TLN2 (APH1B locus) was co-regulated in astro-activated (Figure 5C) and is a component of the actin cytoskeleton linking to focal adhesion plaques, which have been shown to have higher concentrations of cholesterol than the surrounding membrane<sup>51</sup>. Even though the genes were not necessarily the same across the cell states, the consistency of genes within

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

these loci clustering with *APOE*, and many relating to lipid metabolism, suggests common regulatory mechanisms behind these loci and *APOE*.

These findings suggest that the regulatory networks involving *APOE* and the identified transcription factors extend beyond *APOE* itself and involve other genes associated with AD.

Many of these AD-GWAS genes are related to critical immune, lysosome, lipid, and energy metabolism pathways highlighted by the previous TF and gene set enrichment analyses. It also

supports the notion that some GWAS loci have many genes that can simultaneously influence




Figure 5 Other AD GWAS genes are coregulated with APOE (A,B) Genes (A) in AD GWAS loci (B) that are co-regulated by APOE-regulating TFs. Genes co-regulated by APOE-TFs were those differentially expressed (Mann-Whitney Rank U) between the original expression profiles and the perturbed values following virtual TF-KO. (C,D) Genes (C) in AD GWAS loci (D) that co-clustered with APOE in the co-regulation networks. Principle component analysis was performed on the TF-by-target gene matrix. The top five principal components were used to calculate the UMAP coordinates. Gene clusters were calculated from a shared-nearest-neighbor graph using the Louvain algorithm. Rows are colored by loci. Some genes are within two loci and therefore have two colors. These plots are truncated; the full plots can be found in Supplementary Figure 6.

#### Discussion

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

We used GRNs to elucidate the cell-type- and -state-specific regulation of APOE. These analyses revealed that APOE and its co-regulated genes were modulated by several transcription factor (TF) families, including CEBP, JUN, FOS, FOXO, and THR. The CEBP (A/B/D/B), JUN (/B/D), and FOS (/L2) families were involved in APOE regulation in all microglial states, whereas FOXO (1/3) was specific to the mic-inflammatory state. Despite the consistency of the CEBP, JUN, and FOS families across microglial states, the individual members had different strengths and associations based on cell state suggesting individual TFs could more strongly promote one state over another. The CEBP family of TFs form homo- and heterodimers with each other, so the proportions of these dimers could influence cell state. Additional experimental studies are needed to better understand the interplay between members of these families and how they regulate the activation states of microglia. Interestingly, CEBPB and JUND also regulated the APOE gene cluster in the astro-resting state, suggesting that these TF families play a role in APOE regulation in both microglia and astrocytes. APOE in astro-activated was controlled by the known APOE regulator THRB<sup>16</sup>, and NR2F1 and RARB, two other members of the steroid/thyroid hormone receptor family. We previously reported an upregulation of THRB in the mic-activated state compared to the other microglia states, implying that the THR family of TFs could influence APOE expression in microglia as well, but to a lower degree<sup>5</sup>. Further studies are required to confirm this conclusion. These GRNs identified associations with immunoglobulin binding, IL1B/IL6/cytokine production, glycolysis, endocytosis, macroautophagy, mitochondrial electron transport, fatty-acyl-CoA biosynthesis, glucan catabolism, and amide metabolism. Related to immunoglobulin binding, AD GWAS associated genes FCER1G, FCGR2A, and FCGR3A are Fc immunoglobulin receptors that bind to IgE and IgG and were coregulated with APOE in microglia. Usually, IgE and IgG cannot cross the blood-brain-barrier (BBB), but it has been suggested that in APOEe4 carriers, the vasculature and endothelial cells making up the BBB are compromised, and albumin, antibodies, cytokines, and other inflammatory molecules more easily cross into the brain<sup>52,53</sup>. This might account for the association between this biology and APOE. It might also explain how periodontitis, a peripheral infection, could increase AD risk in association with FCGR3A<sup>41</sup>.

Additionally, when microglia and astrocytes encounter these inflammatory signals, they propagate the signal by producing their own IL1B, IL6, and other cytokines, as suggested by these GRNs<sup>54–56</sup>. Astrocytes also boost their cholesterol production in response to cytokine signaling<sup>53</sup>. Within astro-activated, we saw many APOE-related genes pointing to fatty-acyl-CoA biosynthesis, a precursor to cholesterol. APOE is one of the key molecules transporting this newly synthesized cholesterol to the surrounding cells. Evidence indicates that increases in cholesteryl ester, the storage molecule for excess cholesterol, increase the accumulation of phosphorylated tau (pTau) by reducing the proteasome protein units<sup>57,58</sup>. Studies have also suggested that this increased cholesterol enlarges the lipid rafts, influencing many associated receptors 53,59,60. For instance, APP, BACE1, TREM2, MS4A, TLR4, Fc immunoglobulin receptors, and GLUT1 are all associated with lipid rafts<sup>53,59-61</sup>. Our analysis shows that other AD GWAS genes are co-regulated with APOE; some are also associated with cholesterol levels in the membrane, including MARCKS, PRN1, and TLN2. In neurons, APP is upregulated and preferentially beta-cleaved when associated with lipid rafts which is amyloidogenic<sup>59,60</sup>. TREM2, TLR4, IFNGR, and TNFA are all receptors that rely upon clustering as a part of their activation<sup>53</sup>, and increased cholesterol mediates this clustering, enhancing the activation of these cells, again highlighting the connection between cytokines and the APOE-related genes. Astrocytes are the primary support cells of the brain and are in contact with the vasculature to facilitate the uptake and delivery of essential molecules to the neurons and other cells. GLUT1 transports glucose into astrocytes through the endfeet, but evidence suggests that GLUT1 is less efficient when incorporated into large lipid rafts induced by increased cholesterol<sup>62,63</sup>. This might explain why the mitochondrial electron transport chain is associate with astro-resting, while glucan catabolism, or the breakdown of glycogen into glucose, is linked to astro-activated state. Other studies have reported a reduction in glucose uptake in AD<sup>36</sup>. Interestingly, while extra cholesterol decreases glucose uptake, it increases neuronal energy demand by promoting neurotransmitter release in presynapses and the endocytosis and internalization of receptors in postsynapses<sup>64</sup>. This energy demand stimulates the transport of lactate and ketones from astrocytes to neurons, enabling increased neural activation by bypassing the rate-limiting step of glycolysis in energy production<sup>36,65</sup>. Evidence shows that in young APOEe4 carriers, there is an

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

436 increase in cognitive performance and neuronal activity, suggesting this biology is 437 occurring<sup>36,66,67</sup>. With age we see the negative aspects of this increased neuronal activity. 438 Neuronal activity produces reactive oxygen species (ROS), so these hyperactive neurons 439 produce increased quantities of ROS which then peroxidate the fatty acids (pFA) found in the 440 cell and organelle membranes<sup>68</sup>. These pFA are toxic, so the neurons expel them with the help of APOE. Over time, ROS and pFA build up in the neuron, causing neurotoxicity, especially in 441 442 APOEe4 carriers with less efficient binding and, therefore, export of lipids. The expelled pFA is 443 then picked up by microglia and astrocytes and stored in lipid droplets (LD), which is consistent 444 with our finding GO terms, TFs (MAF and CEBPB), and GWAS genes (RABEP1) related to 445 endocytosis. This is also concordant with our finding that BHLHE40, a regulator for the clearance 446 of lipid-rich cellular debris, is an APOE regulator. Excess cholesterol produced by astrocytes also 447 collects in the lysosome, where it causes lysosomal dysfunction, leading to the buildup of autophagosomes and mitochondrial dysfunction<sup>36</sup>. This is consistent with many of the co-448 449 regulated GWAS genes we identified, including PGRN, CTSH, CTSB (lysosome), SQSTM1 450 (autophagosomes), SLC25A11, and LACTB (mitochondria metabolism). 451 Our findings also show that many TFs regulating APOE and the APOE gene clusters are related to 452 circadian rhythm, including BHLHE40, DBP, XBP1, CREM, SREBF1, FOXO3, and NR2F1. This is 453 consistent with many studies that have reported an association between AD and disrupted 454 sleep due to circadian rhythm dysfunction 33,66,69-71. These findings highlight the importance of 455 the circadian rhythm in regulating APOE expression and function. Interestingly, NR2F1 is 456 associated with BBSOA, a neurodevelopmental disease characterized by the loss of retinal 457 ganglion cells<sup>32</sup>. Another study with APOE<sup>-/-</sup> reported the loss of melanopsin-expressing ganglion 458 cells in the suprachiasmic nucleus, resulting in the loss of light entrainment<sup>33</sup>, the process by 459 which light synchronizes the biological clock with the environment. These studies suggest that 460 NR2F1 and APOE are connected and involved in the circadian rhythm, as indicated by our GRNs. 461 Furthermore, the disruption of energy metabolism and the suggested increase in ketone 462 metabolism are modulated by  $AMPK^{72}$ . AMPK also degrades the circadian proteins *Per* and *Cry*, which are produced by the transcriptional activation of Clock and Bmal173. Per and Cry form a 463 464 complex with CK1E/D and inhibit the transcription of Clock, Bmal1, Per, and Cry, creating a

negative feedback loop. The degradation of Per and Cry by AMPK breaks this loop and results in the overexpression of Clock and Bmal1, as well as their downstream targets, such as NR1D1, which encodes the Rev-ERB $\alpha$  protein. NR1D1 represses Cx3cr1, a marker of homeostatic microglia, thus activating microglia and influencing lipid droplet formation 74,75. Disruption of the circadian rhythm is associated with impaired function and integrity of the endothelial and vascular smooth muscle cells, causing inflammation and passing these inflammatory markers through a weakened BBB<sup>73</sup>. It is also related to energy metabolism during the fasting stage of sleep<sup>26</sup>. Overall, our results reemphasize the connection of AD to circadian rhythm and suggest that APOE and lipid biology are key contributors. In general, the TF families primarily associated with microglia suggest a relationship between immunity and APOE, while the TF family associated with astrocytes suggests a link between APOE and lipid metabolism. This is consistent with the primary function of each of these cell types. In astrocytes, the evidence points to the primary purpose of APOE in lipid metabolism is to shuttle cholesterol and other lipids synthesized by the astrocytes to other cells. The primary purpose of APOE in immunity is not quite as clear in microglia. A promising possibility is the secretion of extracellular vesicles (EVs) that are induced upon microglial activation. The biology related to these EVs is closely tied with that of the endosomal-lysosomal system<sup>76</sup>, highlighted in our GRNs. These EVs can contain RNA, protein, lipids, and cytokines for extracellular communication<sup>77</sup>. A study in *Apoe<sup>-/-</sup>* mice on a high-fat diet highlighted the role of *Apoe* in influencing the miRNA composition of EVs secreted by these macrophages and their impact on atherosclerosis<sup>78</sup>. Although most studies on EVs interrogate their miRNA composition, other studies suggest differences in lipid composition based on microglia state as well<sup>79</sup>, including increased secretion of cholesterol in EVs in response to increased free cholesterol<sup>80</sup>. APOE could play a role in the transfer of lipids to these EVs. A limitation of this study is that pySCENIC utilizes only a single modality, co-expression, to identify relationships between TFs and target genes, unlike the newer SCENIC+, which also incorporates chromatin accessibility. Despite this, pySCENIC has successfully identified biologically relevant TF-target interactions. We presume that TFs regulating the APOE gene clusters within the co-regulatory networks influence APOE, even in the absence of direct TF-

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

APOE links in the pySCENIC results. Nevertheless, the findings underscore many known features of AD and establish a link to APOE biology. Moreover, the discovery cohort includes carriers of APOE, TREM2, APP, and PSEN1 variants, all of which could influence the GRNs in ways not accounted for. Additionally, the cohort's European ancestry may restrict the generalizability of these results to other, less represented populations.

In conclusion, the TFs and pathways associated with APOE all support known AD pathology and support the building evidence implicating lipids as a key driver of AD-related pathology.

### Methods

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

Single nucleus RNA-seq acquisition and integration

Human snRNA-seq data of the parietal lobe from the Knight ADRC and DIAN was gathered at NIAGADs (accession number NG00108) and upon request from DIAN. These data include a total of 67 neuropathological controls, sporadic AD, and autosomal dominant AD participants. An independent human snRNA-seq dataset from ROSMAP (dorsolateral prefrontal cortex) was collected from Synapse (synapse ID syn21125841). The ROSMAP data has 11 sporadic AD, 11 TREM2 R62H, and 10 control participants. The microglia from the ROSMAP dataset was previously integrated with the microglia from the Knight and DIAN data<sup>5</sup>. The ROSMAP astrocytes were integrated as a part of this study using the same process described by Brase, et al. Briefly, we isolated and normalized the astrocytes with Seurat's (v.4.3.0) SCTransform, setting "return.only.var.genes" to FALSE and regressing out "nCount RNA" and "nFeature RNA". We integrated the astrocytes with 3000 features in SelectIntegrationFeatures, PrepSCTintegration, our data as reference in FindIntegrationAnchors, and IntegrateData. We clustered integrated data with ten principal components in FindNeighbors and resolution 15 in FindClusters. We gave each cluster an 'original' identity by isolating our nuclei from clusters and finding the most common original ID. We transferred this ID to ROSMAP nuclei like a k-nearest neighbor classifier. We mapped cluster identities to pre-integrated normalized ROSMAP data.

520

521

522

523

524

525

526

527

528

529

530

#### Gene regulatory network prediction by pySCENIC

We created cell-state-specific GRNs using the python implementation of the SCENIC<sup>81</sup> analysis method called pySCENIC<sup>7</sup> (version 0.12.1). We isolated the cell type of interest and filtered the genes to those that were expressed in ≥5% of the cell type population. Then we isolated the cell expression states of interest. We ran pySCENIC on each individual cell state 100 times (different seed for each run) as suggested by pySCENIC. We employed default values for all parameters and provided default reference data downloaded from <a href="https://resources.aertslab.org/cistarget/">https://resources.aertslab.org/cistarget/</a>: Database (hg38\_500bp\_up\_100bp\_down\_full\_tx\_v10\_clust.genes\_vs\_motifs.rankings, hg38\_10kbp\_up\_10kbp\_down\_full\_tx\_v10\_clust.genes\_vs\_motifs.rankings), table (motifs-v10nr\_clust-nr.hgnc-m0.001-o0.0.tbl), and transcription factor list (allTFs\_hg38.txt). An

additional TF list was downloaded from http://humantfs.ccbr.utoronto.ca/download/v 1.01/TF names v 1.01.txt and the two lists were merged totaling 2093 TFs. After the 100 runs were complete, we identified the transcription factors (TFs) that were present in >= 80% of the runs. We then ran pySCENIC an additional 100 times using only the >=80% TFs labeled as transcription factors. The other TFs were retained in the expression matrix, but not labelled as TFs. The TFs that appeared in >= 80% of the second round of runs were isolated as reproducible regulators. The same resource files and parameters were used in the ROSMAP cohort replication. We filtered the genes to those intersecting those from the Knight ADRC microglia and astrocyte runs. We ran pySCENIC 100 times using the filtered list of TFs for each respective cell state (list used in second round of discovery runs). We isolated the TFs that were present in >= 50% of the runs. We intersected the final lists of discovery TFs with the lists of replication TFs to identify a

**Co-regulation network clusters** 

set of replicable TFs for each cell state.

Using the TF-target gene matrices for cell state, we identified co-regulation network clusters and visualized them in the UMAP space. The TF-target gene matrix had each of the replicable TFs as features, the target genes as elements, and the values were the number of times the target gene was regulated by the TF out of the 100 pySCENIC runs. These values were normalized by the number of times the TF was included in the pySCENIC networks. For example, if TF\_1 was in the pySCENIC networks 85 times, all the values would be multiplied by (100/85) to get the normalized value. We then log transformed the values and ran them through a principal component analysis using *prcomp*, a native R (v4.2.2) function. We then passed the top five principal components (PCs) through the *umap* function from the umap library (v0.2.10.0) to create a two-dimensional representation of the space. The top five PCs were also passed to the *makeSNNGraph* function from the bluster package (v1.8.0) to create a shared nearest neighbor graph. The resulting graph was passed to the *cluster\_louvain* function from the igraph package (v1.3.5) to identify clusters of similarly regulated target genes using a resolution of 2. All target

genes in the same cluster as APOE were considered co-regulated with APOE and were evaluated for additional AD GWAS genes and for gene set enrichment (Supplementary Table 6).

### TF regulators for gene clusters

We identified the TFs significantly upregulating the genes in each gene cluster identified in the gene UMAPs. We utilized the normalized, but not log transformed, TF-target gene matrix described in the Gene UMAP clusters section. For each gene cluster at a time, we created a binary vector where 1 indicated the target gene was in the cluster. We then looped through each TF and modelled the TF-target gene values using the binary vector as a covariate. The native *glm* R function (v4.2.2) was used to train the model with a quasipoisson distribution and log link function. The hits for each cluster were then multiple testing corrected using the Benjamini-Hochberg (BH) method. TFs with a BH corrected p-value less than 0.05 and an estimate greater than zero were considered significant regulators for the gene cluster.

#### In silico transcription factor knock-out

SCENIC+<sup>17</sup> was recently released with the functionality to knockout a TF and determine the shift in the expression space. We implemented the algorithm proposed in SCENIC+ (v1.0.0, python v3.8.18), which was an adaption from the original method in CellOracle<sup>82</sup>. In summary, this method uses the cell by gene expression matrix to train prediction models for each gene. These models allow for the virtual knockout of a TF (TF-KO) by setting the expression of the TF to zero and then using the trained models to predict the shift in target gene expression. The expression shift is then transformed back onto the reduction space and depicted by arrows.

By default, SCENIC+ used the GradiantBoostingRegressor from sklearn (v1.3.2) with a learning rate of 0.01, 500 estimators, and max features set to 0.1 to train prediction models. We included the TFs that were regulating a target gene at least 5% of the time in the model that used TF expression to predict the target gene expression. To correct for the influence of sample proportion on each cell state, we also included the log transformed nuclei counts for the sample in the prediction model. SCENIC+ uses a default of five iterations to propagate the shift across the expression matrix. We extended SCENIC+'s implementation to work with the UMAP space rather than just the PCA space. We also switched the arrows to be drawn by the quiver function

as was found in the CellOracle implementation rather than the streamplot function used by SCENIC+.

To extend this method to the UMAP space, we trained a neural network to predict a cell's UMAP coordinates using as input the expression levels of all genes (python v3.11.0). We used the original gene expression matrix (GEM) and UMAP representation for the cell types which included all expression states not just the resting and activated states passed to pySCENIC. First, we log transformed the GEM. We then used the train\_test\_split function from sklearn (v1.3.2) to split the data into training and testing data (80% training, 20% testing) and stratified by cell state. We then split the training data into training and validation sets (90% training, 10% validation) and once again stratified by cell state. Using the StandardScaler function from sklearn (v1.3.2) we fit and transformed a scaler using the training GEM. This scaler was then used to transform the validation and test GEMs. The sequential neural network was constructed using tensorflow (v2.14.0) and consisted of three layers: two dense layers with the ReLU activation function and an output layer with the same dimensionality as the UMAP data (n=2). The model was compiled with the Adam optimizer and mean squared error loss function. Early stopping was implemented to prevent overfitting with monitoring set to 'val loss' and a patience of 10. The model was then trained on the training data for a maximum of 1000 epochs. The trained model was evaluated on the test GEM. This trained model was used on the TF-KO perturbed matrices to transform the expression shift to the UMAP reduction space. This method was incorporated into a snakemake pipeline so that TF-KO could be performed consistently across TFs, cell states, and cell types.

#### TF knockout differential expression

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

We performed a differential expression analysis between the original GEM and perturbed GEM calculated after TF-KO. The original GEM and perturbed GEM were both log transformed. We then filtered out the cells that had zero expression of the TF in the original matrix as these cells have no changes in expression and would skew the results. We then performed a Mann-Whitney rank U test using the *mannwhitneyu* function from scipy (v1.2.2, python v3.11.0) to identify differentially expressed genes. We performed FDR multiple testing correction. Genes

619 with a corrected p-value less than 0.05 were considered co-regulated with APOE and were 620 evaluated for additional AD GWAS genes and for gene set enrichment (Supplementary Table 6). 621 622 Gene set enrichment of genes co-regulated with APOE 623 Sets of co-regulated genes where run through enrichment analysis to better understand the 624 related function. There were two sources of co-regulated genes, co-regulation network clusters 625 and TF-targets, and they were analyzed independently. The gene sets identified by gene clusters 626 were run through enrichment analysis using the enrichr function from the enrichR package 627 (v3.1) in R (v4.2.2) and the TF-targets were run through the enrichr function from the gseapy 628 package (v0.9.5) in python (v3.11.0). Both used the 2023 GO Biological Process (BP) terms and 629 significant associations were those with adjusted p-values less than 0.05. 630 The terms from the TF-targets analysis were condensed using rrvgo (v1.6.0), an R package that implements the Revigo<sup>83</sup> tool for summarizing GO BP terms. The function *calculateSimMatrix* 631 632 was used to calculate the relationships between the GO BP terms with variable inputs: orgdb = "org.Hs.eg.db", ont = "BP", method = "Rel". The terms were then summarized using 633 634 reduceSimMatrix and the following variables: score = "Rank", threshold = .7, orgdb = "org.Hs.eg.db". The summarized terms or "parentTerms" and their P values were then 635 636 used to make a heatmap. Rows and columns were ordered using dist function 637 method = "manhattan". 638 Identifying other AD GWAS genes co-regulated APOE 639 There were two sources of co-regulated genes, co-regulation network clusters and TF-targets, 640 and they were analyzed independently. These gene sets were compared against a list of genes 641 within GWAS loci (+/- 500KB of the lead SNP, Supplementary Table 7) and can be found in 642 Supplementary Table 6. The Loci for each source were identified and merged. This merged list 643 was used to consistently color the genes and loci for each row in the upset plots in Figure 5. 644 Data Availability 645 The single nucleus data from the Knight ADRC accessed in this study are found in the National 646 Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) with accession 647 number NG00108 [https://www.niagads.org/datasets/ng00108]. The raw single nucleus data

648	from the DIAN brain bank accessed in this study are available under restricted access to
649	maintain individual and family confidentiality. These samples contain rare disease-causing
650	variants that could be used to identify the participating individuals and families. Access can be
651	obtained by request through the online resource request system on the DIAN Website:
652	https://dian.wustl.edu/our-research/for-investigators/dian-observational-study-investigator-
653	resources/. The ROSMAP single nucleus RNA sequencing data used in this study are available at
654	Synapse under Synapse ID syn21125841
655	[https://www.synapse.org/#!Synapse:syn21125841/wiki/597278]. The pySCENIC default
656	reference data was downloaded from https://resources.aertslab.org/cistarget/: Database
657	[https://resources.aertslab.org/cistarget/databases/homo_sapiens/hg38/refseq_r80/mc_v10_c
658	ust/gene_based/hg38_500bp_up_100bp_down_full_tx_v10_clust.genes_vs_motifs.rankings.fea
659	ther],
660	[https://resources.aertslab.org/cistarget/databases/homo_sapiens/hg38/refseq_r80/mc_v10_c
661	ust/gene_based/hg38_10kbp_up_10kbp_down_full_tx_v10_clust.genes_vs_motifs.rankings.fea
662	ther], table [https://resources.aertslab.org/cistarget/motif2tf/motifs-v10nr_clust-nr.hgnc-
663	m0.001-o0.0.tbl], and transcription factor list
664	[https://resources.aertslab.org/cistarget/tf_lists/allTFs_hg38.txt]. An additional TF list was
665	$downloaded\ from\ [http://humantfs.ccbr.utoronto.ca/download/v\_1.01/TF\_names\_v\_1.01.txt].$
666	Source data are provided with this paper.
667	Code Availability
668	Custom code used to analyze the snRNA-seq data and datasets generated and/or analyzed in
669	the current study are available from the corresponding authors upon request or at
670	https://github.com/HarariLab/APOE-GRN.
671	
672	

# 673 References

- 1. Ulrich, J. D. et al. ApoE facilitates the microglial response to amyloid plaque pathology. J.
- 675 Exp. Med. **215**, 1047–1058 (2018).
- 2. Singh, D. Astrocytic and microglial cells as the modulators of neuroinflammation in
- Alzheimer's disease. J. Neuroinflammation 19, 206 (2022).
- 3. Eskandari-Sedighi, G. & Blurton-Jones, M. Microglial APOE4: more is less and less is more.
- 679 *Mol. Neurodegener.* **18**, 99 (2023).
- 4. Fernandez, C. G., Hamby, M. E., McReynolds, M. L. & Ray, W. J. The Role of APOE4 in
- Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer's
- Disease. Front. Aging Neurosci. 11, (2019).
- 5. Brase, L. et al. Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease
- and risk variant carriers. *Nat. Commun.* **14**, 2314 (2023).
- 685 6. Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent
- and TREM2-independent cellular responses in Alzheimer's disease. Nat. Med. 26, 131–142
- 687 (2020).
- 7. Van de Sande, B. et al. A scalable SCENIC workflow for single-cell gene regulatory network
- analysis. *Nat. Protoc.* **15**, 2247–2276 (2020).
- 8. Kunkle, B. W. et al. Novel Alzheimer Disease Risk Loci and Pathways in African American
- 691 Individuals Using the African Genome Resources Panel: A Meta-analysis. JAMA Neurol. 78,
- 692 102–113 (2021).
- 693 9. Schwartzentruber, J. et al. Genome-wide meta-analysis, fine-mapping and integrative
- 694 prioritization implicate new Alzheimer's disease risk genes. *Nat. Genet.* **53**, 392–402 (2021).
- 695 10. Lekstrom-Himes, J. & Xanthopoulos, K. G. Biological Role of the CCAAT/Enhancer-binding
- 696 Protein Family of Transcription Factors\*. J. Biol. Chem. 273, 28545–28548 (1998).
- 697 11. Gao, T. et al. Transcriptional regulation of homeostatic and disease-associated-microglial
- 698 genes by IRF1, LXRβ and CEBPα. *Glia* **67**, 1958–1975 (2019).
- 699 12. Xia, Y. et al. C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4
- expression in Alzheimer's disease. *Mol. Psychiatry* **26**, 6002–6022 (2021).

- 13. Ejarque-Ortiz, A. et al. CCAAT/enhancer binding protein delta in microglial activation. J.
- 702 *Neurosci. Res.* **88**, 1113–1123 (2010).
- 703 14. Li, Z. et al. Interferon Regulatory Factor 7 Promoted Glioblastoma Progression and Stemness
- by Modulating IL-6 Expression in Microglia. *J. Cancer* **8**, 207–219 (2017).
- 705 15. Angel, P. & Schorpp-Kistner, M. Jun/Fos. in *Encyclopedic Reference of Genomics and*
- 706 Proteomics in Molecular Medicine 928–935 (Springer, Berlin, Heidelberg, 2006).
- 707 doi:10.1007/3-540-29623-9\_4560.
- 16. Roman, C. et al. Thyroid hormones upregulate apolipoprotein E gene expression in
- 709 astrocytes. *Biochem. Biophys. Res. Commun.* **468**, 190–195 (2015).
- 710 17. Bravo González-Blas, C. et al. SCENIC+: single-cell multiomic inference of enhancers and
- 711 gene regulatory networks. *Nat. Methods* **20**, 1355–1367 (2023).
- 18. Honma, S. et al. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature
- **419**, 841–844 (2002).
- 19. Kawamoto, T. et al. A novel autofeedback loop of Dec1 transcription involved in circadian
- 715 rhythm regulation. *Biochem. Biophys. Res. Commun.* **313**, 117–124 (2004).
- 716 20. Cho, Y. et al. The Basic Helix-Loop-Helix Proteins Differentiated Embryo Chondrocyte (DEC) 1
- and DEC2 Function as Corepressors of Retinoid X Receptors. *Mol. Pharmacol.* **76**, 1360–1369
- 718 (2009).
- 719 21. Yoshitane, H. et al. Functional D-box sequences reset the circadian clock and drive mRNA
- 720 rhythms. *Commun. Biol.* **2**, 1–10 (2019).
- 721 22. Podlesny-Drabiniok, A. et al. BHLHE40/41 regulate macrophage/microglia responses
- 722 associated with Alzheimer's disease and other disorders of lipid-rich tissues.
- 723 2023.02.13.528372 Preprint at https://doi.org/10.1101/2023.02.13.528372 (2023).
- 724 23. Yoshida, H., Matsui, T., Yamamoto, A., Okada, T. & Mori, K. XBP1 mRNA is induced by ATF6
- and spliced by IRE1 in response to ER stress to produce a highly active transcription factor.
- 726 *Cell* **107**, 881–891 (2001).
- 727 24. Pan, Y. et al. 12-h clock regulation of genetic information flow by XBP1s. PLOS Biol. 18,
- 728 e3000580 (2020).

- 729 25. Foulkes, N. S., Borjigin, J., Snyder, S. H. & Sassone-Corsi, P. Transcriptional control of
- 730 circadian hormone synthesis via the CREM feedback loop. Proc. Natl. Acad. Sci. 93, 14140–
- 731 14145 (1996).
- 732 26. Lech, K. et al. Dissecting Daily and Circadian Expression Rhythms of Clock-Controlled Genes
- 733 in Human Blood. *J. Biol. Rhythms* **31**, 68–81 (2016).
- 734 27. Sun, N. et al. Human microglial state dynamics in Alzheimer's disease progression. Cell 186,
- 735 4386-4403.e29 (2023).
- 736 28. Yan, D. et al. SIRT1/FOXO3-mediated autophagy signaling involved in manganese-induced
- neuroinflammation in microglia. *Ecotoxicol. Environ. Saf.* **256**, 114872 (2023).
- 738 29. López-Sánchez, N., Ramón-Landreau, M., Trujillo, C., Garrido-García, A. & Frade, J. M. A
- 739 Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice. *Mol.*
- 740 *Neurobiol.* **59**, 3016–3039 (2022).
- 30. Bräuer, A. U., Nitsch, R. & Savaskan, N. E. Identification of macrophage/microglia activation
- factor (MAF) associated with late endosomes/lysosomes in microglial cells. FEBS Lett. **563**,
- 743 41–48 (2004).
- 31. Tocco, C., Bertacchi, M. & Studer, M. Structural and Functional Aspects of the
- Neurodevelopmental Gene NR2F1: From Animal Models to Human Pathology. Front. Mol.
- 746 *Neurosci.* **14**, (2021).
- 32. Bertacchi, M. et al. Mouse Nr2f1 haploinsufficiency unveils new pathological mechanisms of
- a human optic atrophy syndrome. *EMBO Mol. Med.* **11**, e10291 (2019).
- 749 33. Zhou, L. et al. Degeneration and energy shortage in the suprachiasmatic nucleus underlies
- 750 the circadian rhythm disturbance in ApoE-/- mice: implications for Alzheimer's disease. Sci.
- 751 Rep. **6**, 36335 (2016).
- 752 34. Wheeler, M. A. et al. MAFG-driven astrocytes promote CNS inflammation. *Nature* **578**, 593–
- 753 599 (2020).
- 754 35. Szewczyk, L. M. *et al.* Astrocytic β-catenin signaling via TCF7L2 regulates synapse
- 755 development and social behavior. *Mol. Psychiatry* 1–17 (2023) doi:10.1038/s41380-023-
- 756 02281-y.

- 36. Lee, H. et al. ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial
- homeostasis and oxidative phosphorylation in human astrocytes. *Cell Rep.* **42**, 113183
- 759 (2023).
- 37. Williams, H. C. *et al.* APOE alters glucose flux through central carbon pathways in astrocytes.
- 761 Neurobiol. Dis. **136**, 104742 (2020).
- 762 38. Drobny, A. et al. The role of lysosomal cathepsins in neurodegeneration: Mechanistic
- insights, diagnostic potential and therapeutic approaches. *Biochim. Biophys. Acta BBA Mol.*
- 764 *Cell Res.* **1869**, 119243 (2022).
- 765 39. Fu, L. et al. Enhanced expression of FCER1G predicts positive prognosis in multiple
- 766 myeloma. *J. Cancer* **11**, 1182–1194 (2020).
- 40. Fuller, J. P., Stavenhagen, J. B. & Teeling, J. L. New roles for Fc receptors in
- neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. Front. Neurosci.
- 769 **8**, 235 (2014).
- 41. Jin, J. et al. Shared Molecular Mechanisms between Alzheimer's Disease and Periodontitis
- 771 Revealed by Transcriptomic Analysis. *BioMed Res. Int.* **2021**, 6633563 (2021).
- 42. Lanfranco, M. F., Ng, C. A. & Rebeck, G. W. ApoE Lipidation as a Therapeutic Target in
- 773 Alzheimer's Disease. *Int. J. Mol. Sci.* **21**, 6336 (2020).
- 43. Martín, M. G., Pfrieger, F. & Dotti, C. G. Cholesterol in brain disease: sometimes determinant
- and frequently implicated. *EMBO Rep.* **15**, 1036–1052 (2014).
- 776 44. Iyer, D. N. et al. Pathophysiological roles of myristoylated alanine-rich C-kinase substrate
- 777 (MARCKS) in hematological malignancies. *Biomark. Res.* **9**, 34 (2021).
- 778 45. Issara-Amphorn, J. et al. Myristoylated, alanine-rich C-kinase substrate (MARCKS) regulates
- toll-like receptor 4 signaling in macrophages. Sci. Rep. 13, 19562 (2023).
- 780 46. Turco, E. et al. Reconstitution defines the roles of p62, NBR1 and TAX1BP1 in ubiquitin
- 781 condensate formation and autophagy initiation. *Nat. Commun.* **12**, 5212 (2021).
- 782 47. Wu, C.-H. et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis.
- 783 *Nature* **488**, 499–503 (2012).

- 48. Frantzi, M. et al. Silencing of Profilin-1 suppresses cell adhesion and tumor growth via
- predicted alterations in integrin and Ca 2+ signaling in T24M-based bladder cancer models.
- 786 *Oncotarget* **7**, 70750–70768 (2016).
- 49. Gallo, M. et al. MISC-1/OGC links mitochondrial metabolism, apoptosis and insulin
- 788 secretion. *PloS One* **6**, e17827 (2011).
- 789 50. Keckesova, Z. et al. LACTB is a tumour suppressor that modulates lipid metabolism and cell
- 790 state. *Nature* **543**, 681–686 (2017).
- 791 51. Tachibana, H. et al. The plasma membrane of focal adhesions has a high content of
- 792 cholesterol and phosphatidylcholine with saturated acyl chains. J. Cell Sci. 136, jcs260763
- 793 (2023).
- 52. Liu, C.-C. et al. Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by
- 795 compromising cerebrovascular function. *Nat. Neurosci.* **25**, 1020–1033 (2022).
- 796 53. Wang, H. et al. Regulation of Neuroinflammation by Astrocyte-Derived Cholesterol.
- 797 http://biorxiv.org/lookup/doi/10.1101/2022.12.12.520161 (2022)
- 798 doi:10.1101/2022.12.12.520161.
- 799 54. Hanisch, U.-K. Microglia as a source and target of cytokines. *Glia* **40**, 140–155 (2002).
- 55. Choi, S. S., Lee, H. J., Lim, I., Satoh, J. & Kim, S. U. Human Astrocytes: Secretome Profiles of
- 801 Cytokines and Chemokines. *PLOS ONE* **9**, e92325 (2014).
- 56. Sofroniew, M. V. Multiple Roles for Astrocytes as Effectors of Cytokines and Inflammatory
- 803 Mediators. *The Neuroscientist* **20**, 160–172 (2014).
- 57. van der Kant, R. et al. Cholesterol Metabolism Is a Druggable Axis that Independently
- 805 Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons. *Cell Stem Cell*
- **24**, 363-375.e9 (2019).
- 58. Wang, H. et al. Regulation of beta-amyloid production in neurons by astrocyte-derived
- 808 cholesterol. *Proc. Natl. Acad. Sci. U. S. A.* **118**, e2102191118 (2021).
- 59. Lee, S.-I. et al. APOE4-carrying human astrocytes oversupply cholesterol to promote
- 810 neuronal lipid raft expansion and Aβ generation. Stem Cell Rep. **16**, 2128–2137 (2021).

- 811 60. Ehehalt, R., Keller, P., Haass, C., Thiele, C. & Simons, K. Amyloidogenic processing of the
- 812 Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113–123
- 813 (2003).
- 814 61. Mattiola, I., Mantovani, A. & Locati, M. The tetraspan MS4A family in homeostasis,
- 815 immunity, and disease. *Trends Immunol.* **42**, 764–781 (2021).
- 816 62. Koepsell, H. Glucose transporters in brain in health and disease. *Pflüg. Arch. Eur. J. Physiol.*
- **472**, 1299–1343 (2020).
- 818 63. Yan, Q. et al. Mechanistic insights into GLUT1 activation and clustering revealed by super-
- resolution imaging. *Proc. Natl. Acad. Sci.* **115**, 7033–7038 (2018).
- 820 64. Li, D., Zhang, J. & Liu, Q. Brain cell type-specific cholesterol metabolism and implications for
- 821 learning and memory. *Trends Neurosci.* **45**, 401–414 (2022).
- 822 65. Alessandri, B., Gugliotta, M., Levasseur, J. E. & Bullock, M. R. Lactate and glucose as energy
- substrates and their role in traumatic brain injury and therapy. *Future Neurol.* **4**, 209–228
- 824 (2009).
- 825 66. Graybeal, J. J. et al. Human ApoE ε4 Alters Circadian Rhythm Activity, IL-1β, and GFAP in
- 826 CRND8 Mice. J. Alzheimers Dis. 43, 823–834 (2014).
- 827 67. Wu, L., Zhang, X. & Zhao, L. Human ApoE Isoforms Differentially Modulate Brain Glucose and
- 828 Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early
- 829 Intervention. *J. Neurosci.* **38**, 6665–6681 (2018).
- 830 68. Ioannou, M. S. et al. Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced
- 831 Fatty Acid Toxicity. *Cell* **177**, 1522-1535.e14 (2019).
- 832 69. Ke, P. et al. Relationship between circadian genes and memory impairment caused by sleep
- 833 deprivation. *PeerJ* **10**, e13165 (2022).
- 70. Niu, L. et al. Chronic sleep deprivation altered the expression of circadian clock genes and
- aggravated Alzheimer's disease neuropathology. *Brain Pathol.* **32**, e13028 (2022).
- 71. Ni, J. et al. An impaired intrinsic microglial clock system induces neuroinflammatory
- alterations in the early stage of amyloid precursor protein knock-in mouse brain. J.
- 838 *Neuroinflammation* **16**, 173 (2019).

- 72. Guzmán, M. & Blázquez, C. Ketone body synthesis in the brain: possible neuroprotective
- effects. *Prostaglandins Leukot. Essent. Fatty Acids* **70**, 287–292 (2004).
- 73. Zhang, Z. et al. Circadian rhythm and atherosclerosis (Review). Exp. Ther. Med. 20, 96
- 842 (2020).
- 74. Lam, M. T. Y. et al. Rev-Erbs repress macrophage gene expression by inhibiting enhancer-
- 844 directed transcription. *Nature* **498**, 511–515 (2013).
- 75. Lee, J. et al. Microglial REV-ERBα regulates inflammation and lipid droplet formation to drive
- tauopathy in male mice. *Nat. Commun.* **14**, 5197 (2023).
- 76. Eitan, E., Suire, C., Zhang, S. & Mattson, M. P. Impact of lysosome status on extracellular
- vesicle content and release. Ageing Res. Rev. 32, 65–74 (2016).
- 77. Nguyen, M.-A. et al. Extracellular Vesicles Secreted by Atherogenic Macrophages Transfer
- MicroRNA to Inhibit Cell Migration. *Arterioscler. Thromb. Vasc. Biol.* **38**, 49–63 (2018).
- 78. Bouchareychas, L. et al. Macrophage Exosomes Resolve Atherosclerosis by Regulating
- Hematopoiesis and Inflammation via MicroRNA Cargo. Cell Rep. 32, 107881 (2020).
- 79. Gabrielli, M., Raffaele, S., Fumagalli, M. & Verderio, C. The multiple faces of extracellular
- vesicles released by microglia: Where are we 10 years after? Front. Cell. Neurosci. 16,
- 855 (2022).
- 856 80. Strauss, K. et al. Exosome Secretion Ameliorates Lysosomal Storage of Cholesterol in
- Niemann-Pick Type C Disease\*. J. Biol. Chem. 285, 26279–26288 (2010).
- 858 81. Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods
- **14**, 1083–1086 (2017).
- 860 82. Kamimoto, K. et al. Dissecting cell identity via network inference and in silico gene
- 861 perturbation. *Nature* **614**, 742–751 (2023).
- 862 83. Supek, F., Bošnjak, M., Škunca, N. & Šmuc, T. REVIGO Summarizes and Visualizes Long Lists
- 863 of Gene Ontology Terms. *PLOS ONE* **6**, e21800 (2011).

# Acknowledgments

866

- 867 Doctors Bruno A. Benitez, and Oscar Harari contributed equally to this work as co-senior
- authors. Data sharing for this project were supported by The Dominantly Inherited Alzheimer
- Network (DIAN, U19AG032438), funded by the National Institute on Aging (NIA), the
- 870 Alzheimer's Association (SG-20-690363-DIAN), the German Center for Neurodegenerative
- Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the
- 872 Research and Development Grants for Dementia from Japan Agency for Medical Research and
- 873 Development, AMED, and the Korea Health Technology R&D Project through the Korea Health
- 874 Industry Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian
- 875 Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging,
- 876 Brain Canada Foundation, and Fonds de Recherche du Québec Santé. DIAN Study investigators
- have reviewed this manuscript for scientific content and consistency of data interpretation with
- 878 previous DIAN Study publications. We acknowledge the altruism of the participants and their
- families and the contributions of the DIAN research and support staff at each of the
- participating sites for their contributions to this study.
- The results published here are partly based on data obtained from the AD Knowledge Portal
- (https://adknowledgeportal.org). Study data were provided by the Rush Alzheimer's Disease
- 883 Center, Rush University Medical Center, Chicago. Data collection was supported through funding
- by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917
- 885 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac),
- 886 R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus
- 887 RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-
- AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome
- 889 sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health
- 890 (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic
- data can be requested at www.radc.rush.edu.
- This work was possible thanks to the following governmental grants from the National Institute
- 893 of Health: NIA R01AG057777 (OH), R56AG067764 (OH), U01AG072464 (OH), R01AG074012
- 894 (OH), U19AG032438 (RJB), NINDS R01NS118146 (BAB), R21NS127211 (BAB), NIA T32AG058518
- 895 (LB), O.H. is an Archer Foundation Research Scientist.
- This work was supported by access to equipment made possible by the Departments of
- Neurology and Psychiatry at Washington University School of Medicine.
- The funders of the study had no role in the collection, analysis, or interpretation of data, in the
- 899 writing of the report, or in the decision to submit the paper for publication.
- 900 Figure 1 was created with BioRender.com. Bing Copilot was used to improve grammar and flow
- 901 of text.

902

#### **Author Contributions**

- 903 L.B. performed the quality control, bioinformatic analyses, interpreted the results, created the
- 904 figures, and wrote the manuscript. Y.Y. ran the pySCENIC analyses. E.M. was involved in the DIAN
- sample collection, profiling and provided a critical review of the manuscript. O.H. and B.A.B.
- 906 were involved in experiment design, analysis, data interpretation, intellectual contribution, and
- 907 manuscript writing and review.

908	Competing Interests
909	E.M. receives Grant Funding from NIA; Institutional funding from Eli Lilly, Hoffmann-La Roche,
910	Eisai. He is a DSMB member (paid directly) for Alector; Eli Lilly; a Scientific Advisory Board
911	Member (paid directly) for Alzamend, Fondation Alzheimer. He acts as a Consultant/Advisor for
912	Sage Therapeutics, Eli Lilly, Sanofi, AstraZeneca, Hoffmann La-Roche. The other authors have no
913	conflicts of interest to disclose.
914	Supplementary Information
915	Supplementary Informationpdf file